Maruho Co., Ltd. (Headquarters: Osaka, President & CEO: Koichi Takagi, hereafter referred to “Maruho”) and Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori, hereafter referred to “Astellas”) announced that the companies have agreed that Astellas will assign detailing/promotional activities for Protopic ®(generic name: tacrolimus hydrate) in Japan to Maruho on April 1, 2011 and thereafter will transfer its distribution right in Japan to Maruho on April 1, 2014.
In contrast, Astellas will maintain the approval of manufacturing and distribution for Protopic® in Japan.
The companies are committed to promote appropriate use of Protopic® ointment, and aim to realize the improvement of Quality of Life of more patients suffering from atopic dermatitis, through delivering Protopic® ointment.


* Protopic® ointment shall mean Protopic® ointment 0.1% and Protopic® ointment 0.03% for pediatric.